Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 7/20 | 0.39 |
| ▸ | HTR3A | P46098 | 2/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.38 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.38 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.38 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.38 |
| ▸ | HTR3B | O95264 | 1/20 | 0.38 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.38 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL872029 | 1.00 | CHRNA7 (0.39) | CHRNA7HTR3ASCN9ANTRK1NTRK3 | |
| SCHEMBL872030 | 1.00 | CHRNA7 (0.39) | CHRNA7HTR3ASCN9ANTRK1NTRK3 | |
| SCHEMBL3026227 | 0.88 | CHRNA7 (0.44) | CHRNA7HTR3ASCN9ANTRK1HTR3E | |
| SCHEMBL3026238 | 0.88 | CHRNA7 (0.44) | CHRNA7HTR3ASCN9ANTRK1HTR3E | |
| SCHEMBL3026234 | 0.88 | CHRNA7 (0.44) | CHRNA7HTR3ASCN9ANTRK1HTR3E | |
| SCHEMBL8177429 | 0.86 | SCN9A (0.42) | CHRNA7HTR3ASCN9ANTRK1NTRK3 | |
| SCHEMBL871754 | 0.83 | CHRNA7 (0.48) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL871041 | 0.82 | EGFR (0.39) | JAK2 | |
| SCHEMBL871040 | 0.82 | EGFR (0.39) | JAK2 | |
| SCHEMBL870949 | 0.76 | EGFR (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077801-A1 | Chemical Compounds 637 | ALCON RESEARCH, LTD. | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077801-A1 | Chemical Compounds 637 | PDE4A, PDE4B, PDE3B | CHRNA7 289/4885HTR3A 1091/4885SCN9A 2097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.